Strategic change within OSE Immunotherapeutics

The press release of June 3, 2025, informs that the shareholders of OSE Immunotherapeutics, composed of Ms. Dominique Costantini, Mr. Emile Loria, Mr. Alexis Peyroles, as well as MS Medical Synergy SA and Aperana Consulting SARL, have exceeded the thresholds of 5% to 20% of the capital and voting rights. This situation results from a shareholders' agreement entered into on May 27, 2025.

The members of the concert have expressed their intention to change the composition of the board of directors, ignoring any desire to acquire control. The draft resolutions for the general meeting of June 25, 2025, aim to appoint new directors and dismiss certain current members. Finally, the concert does not provide for any major changes to the company or the issuance of new shares.